Skip to main content

Fetal Growth Retardation

3
Pipeline Programs
9
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Leo Pharma
Leo PharmaDenmark - Ballerup
1 program
1
InnohepPhase 41 trial
Active Trials
NCT01390051Completed50Est. Jul 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
GenotonormPhase 33 trials
Active Trials
NCT00174252Completed57Est. Apr 2009
NCT00163189Completed98Est. Dec 2014
NCT00174278Completed14Est. Oct 2006
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Ferumoxytol infusionPhase 11 trial
Active Trials
NCT04839185Completed3Est. Oct 2021
Eppendorf
EppendorfGermany - Hamburg
1 program
EVERREST Developing a Therapy for Fetal Growth RestrictionN/A1 trial
Active Trials
NCT02097667Completed142Est. Feb 2022
Roche
RocheSTAVANGER NORWAY, Norway
1 program
soluble fms-like tyrosine kinase to placental growth factor ratioN/A1 trial
Active Trials
NCT05284474Not Yet Recruiting340Est. Dec 2026
Sanofi
SanofiPARIS, France
1 program
somatropinPHASE_31 trial
Active Trials
NCT00452491Completed306Est. Apr 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Leo PharmaInnohep
PfizerGenotonorm
PfizerGenotonorm
PfizerGenotonorm
Sanofisomatropin
Human BioSciencesFerumoxytol infusion
Rochesoluble fms-like tyrosine kinase to placental growth factor ratio
EppendorfEVERREST Developing a Therapy for Fetal Growth Restriction

Clinical Trials (8)

Total enrollment: 1,010 patients across 8 trials

NCT01390051Leo PharmaInnohep

Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?

Start: Jul 2011Est. completion: Jul 201650 patients
Phase 4Completed
NCT00174252PfizerGenotonorm

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age

Start: Feb 2005Est. completion: Apr 200957 patients
Phase 3Completed
NCT00163189PfizerGenotonorm

Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

Start: Jan 2005Est. completion: Dec 201498 patients
Phase 3Completed
NCT00174278PfizerGenotonorm

Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary

Start: Feb 1997Est. completion: Oct 200614 patients
Phase 3Completed
NCT00452491Sanofisomatropin

MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children

Start: May 1993Est. completion: Apr 2010306 patients
Phase 3Completed
NCT04839185Human BioSciencesFerumoxytol infusion

Placental Lesions in Fetal Growth Restrictions

Start: Apr 2021Est. completion: Oct 20213 patients
Phase 1Completed
NCT05284474Rochesoluble fms-like tyrosine kinase to placental growth factor ratio

Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler

Start: Jun 2024Est. completion: Dec 2026340 patients
N/ANot Yet Recruiting
NCT02097667EppendorfEVERREST Developing a Therapy for Fetal Growth Restriction

EVERREST Developing a Therapy for Fetal Growth Restriction

Start: Mar 2014Est. completion: Feb 2022142 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.